Zemplar (paricalcitol injection) has been approved for the treatment of secondary hyperparathyroidism associated with chronic renal failure. Zemplar is the first vitamin D analog available to treat secondary hyperparathyroidism.
In three placebo-controlled studies, chronic renal failure patients treated with Zemplar achieved a mean parathyroid hormone (PTH) reduction of 30% in six weeks. Additionally there was no difference in incidence of hypercalcemia or hyperphosphatemia when compared to placebo.
In four, placebo-controlled, double blind, multi center studies, there was no significant difference in the incidence rate for adverse events between Zemplar and placebo-treated patients. The three most frequently reported events in the Zemplar clinical studies were nausea, vomiting and edema, which are commonly seen in hemodialysis patients.